<DOC>
	<DOCNO>NCT00759226</DOCNO>
	<brief_summary>This multicenter open label phase 2 trial examines efficacy combination Gemcitabine 1000 mg/m2 ( 30 min ) , Cisplatin 30 mg/m2 ( 90 min ) , Folinic Acid 200 mg/m2 ( 30 min ) 5-FU 750 mg/m2 ( 24h CI ) give day 1,8 q D22 patient inoperable esophageal cancer . The combination consider suitable evaluation freedom progression rate ( PR+CR+SD ) 60 % interest rate le 40 % . Given alpha error 5 % beta error 10 % least 66 evaluable patient need base 2-Stage Simon design first evaluation 25 evaluable patient .</brief_summary>
	<brief_title>Chemotherapeutic Trial With Gemcitabine , Cisplatin , 5-FU Folinic Acid Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Age &gt; =18 Histologically proven inoperable esophageal cancer Karnofsky Performance status &gt; =60 % Estimated life expectancy &gt; 12 week Measurable disease No oncologic therapy Measurable disease Adequate bone marrow function Geographic proximity compliance Informed consent Negative pregnancy test adequate contraception Insufficient hepatic renal function Elevated serum calcium Pregnancy/breast feeding Active infection Other malignancy Systemic tumour complication require emergency intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>5-FU</keyword>
	<keyword>Folinic Acid</keyword>
	<keyword>inoperable esophageal cancer</keyword>
</DOC>